PSA Glycomics Assay for Early Detection of Prostate Cancer
PSA Glycomics Assay for Early Detection of Prostate Cancer
The principal aim of this pilot study is to test whether the PSA Glycomics Assay on urine and
 serum samples can provide insights regarding the disease state of patients with elevated PSA
 concentrations, as well as to accurately identify if the patient has prostate cancer and, in
 the case of prostate cancer, to determine its level of aggressiveness.
Inclusion Criteria:

 -  Patients with elevated PSA (>3 ng/mL)

 -  Signed informed consent

 Exclusion Criteria:

 -  Patients that have a cystitis (bladder infection)

 -  Patients under chemotherapy

 -  Patients using 5-alpha reductase inhibitors

 -  History or presence of cancers, or non-prostate urological disorders.